The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
Open accessAbstract
Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB). The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation. Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix. These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics. This article highlights some of the issues of nanotechnology relevant to the anti-TB drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Nanosuspensions in drug delivery
Rabinow, B. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1494 · Cited by 1,524
Solid lipid nanoparticles for parenteral drug delivery
Wissing, S. A., Kayser, O., & Müller, R. H. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.12.002 · Cited by 1,495
PLGA Nanoparticles in Drug Delivery: The State of the Art;
Bala, I., Hariharan, S., & Kumar, M. R. (2004) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v21.i5.20 · Cited by 739
Nanocapsule Technology: A Review
Couvreur, P., Barratt, G., Fattal, E., & Vauthier, C. (2002) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v19.i2.10 · Cited by 555
Trojan particles: Large porous carriers of nanoparticles for drug delivery
Tsapis, N., Bennett, D., Jackson, B., Weitz, D. A., & Edwards, D. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182233999 · Cited by 546
Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications
Vauthier, C., Dubernet, C., Fattal, E., Pinto-Alphandary, H., & Couvreur, P. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00041-3 · Cited by 527
Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications
Pinto-Alphandary, H., Andremont, A., & Couvreur, P. (2000) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(99)00121-1 · Cited by 428
Pandey, R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg477 · Cited by 388
Cited by
Huh, A. J., & Kwon, Y. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.002 · Cited by 1,864
Ge, Z., & Liu, S. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60048c · Cited by 914
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-M. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 886
Inhaled nanoparticles—A current review
Yang, W., Peters, J. I., & Williams, R. O. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.02.011 · Cited by 666
Nanoparticles for drug delivery to the lungs
Sung, J. C., Pulliam, B. L., & Edwards, D. A. (2007) · Trends in Biotechnology · doi:10.1016/j.tibtech.2007.09.005 · Cited by 643
Nano-selenium and its nanomedicine applications: a critical review
Hosnedlova, B., Kepinska, M., Skalickova, S., Fernandez, C., Ruttkay-Nedecky, B., Peng, Q., Baron, M., Melcova, M., Opatrilova, R., Zidkova, J., et al. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s157541 · Cited by 630
Nanoparticles: Health Effects—Pros and Cons
Gwinn, M. R., & Vallyathan, V. (2006) · Environmental Health Perspectives · doi:10.1289/ehp.8871 · Cited by 571
Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations
Chidambaram, M., Manavalan, R., & Kathiresan, K. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j30c7d · Cited by 566
Polymeric Nanostructures for Imaging and Therapy
Elsabahy, M., Heo, G. S., Lim, S.-M., Sun, G., & Wooley, K. L. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00135 · Cited by 508
Targeted delivery of nanoparticles for the treatment of lung diseases
Azarmi, S., Roa, W. H., & Löbenberg, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.006 · Cited by 440
“The same approach can be taken for the management of tuberculosis: Nanoparticles with their special characteristics can improve drug bioavailability and reduce the dosing frequency, and may resolve the problem of non-adherence to prescribed therapy and improve patient compliance, which is one of the major obstacles in…”
BackgroundNanotechnology-based approaches in anticancer research
Kamal, M. A., Jabir NR, N., Tabrez, Ashraf, Shakil, & Damanhouri (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33838 · Cited by 363
Nanomedicine and drug delivery: a mini review
Mirza, A. Z., & Siddiqui, F. A. (2014) · International Nano Letters · doi:10.1007/s40089-014-0094-7 · Cited by 353
Anitha, A., Maya, S., Deepa, N., Chennazhi, K. P., Nair, S. V., Tamura, H., & Jayakumar, R. (2011) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2010.08.008 · Cited by 347
Deng, S., Gigliobianco, M. R., Censi, R., & Di Martino, P. (2020) · Nanomaterials · doi:10.3390/nano10050847 · Cited by 329
Therapeutic application of peptides and proteins: parenteral forever?
Antosova, Z., Mackova, M., Kral, V., & Macek, T. (2009) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.07.009 · Cited by 324
Debele, T. A., Mekuria, S. L., & Tsai, H.-C. (2016) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.05.121 · Cited by 317
Control of Biofilm Formation: Antibiotics and Beyond
Algburi, A., Comito, N., Kashtanov, D., Dicks, L. M. T., & Chikindas, M. L. (2017) · Applied and Environmental Microbiology · doi:10.1128/aem.02508-16 · Cited by 299
Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System
Kingsley, J. D., Dou, H., Morehead, J., Rabinow, B., Gendelman, H. E., & Destache, C. J. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9032-4 · Cited by 280
Nanodiamond–insulin complexes as pH-dependent protein delivery vehicles
Shimkunas, R. A., Robinson, E., Lam, R., Lu, S., Xu, X., Zhang, X.-Q., Huang, H., Osawa, E., & Ho, D. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.004 · Cited by 267
New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery
Sosnik, A., Carcaboso, Á. M., Glisoni, R. J., Moretton, M. A., & Chiappetta, D. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.023 · Cited by 264
Advancements in microfluidics for nanoparticle separation
Salafi, T., Zeming, K. K., & Zhang, Y. (2017) · Lab on a Chip · doi:10.1039/c6lc01045h · Cited by 261
Clemens, D. L., Lee, B.-Y., Xue, M., Thomas, C. R., Meng, H., Ferris, D., Nel, A. E., Zink, J. I., & Horwitz, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06049-11 · Cited by 260
Li, C., Liu, H., Sun, Y., Wang, H., Guo, F., Rao, S., Deng, J., Zhang, Y., Miao, Y., Guo, C., et al. (2009) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjp002 · Cited by 260
Toxicology and Drug Delivery by Cucurbit[n]uril Type Molecular Containers
Hettiarachchi, G., Nguyen, D., Wu, J., Lucas, D., Ma, D., Isaacs, L., & Briken, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010514 · Cited by 254
Like a Bolt from the Blue: Phthalocyanines in Biomedical Optics
Sekkat, N., Bergh, H. V. D., Nyokong, T., & Lange, N. (2011) · Molecules · doi:10.3390/molecules17010098 · Cited by 252
Pharmaceutical nanotechnology: from the bench to the market
Mazayen, Z. M., Ghoneim, A. M., Elbatanony, R. S., Basalious, E. B., & Bendas, E. R. (2022) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-022-00400-0 · Cited by 208
“These medications’ therapeutic concentrations in tissues were kept for 10 days, but free drugs only lasted 1 day in the plasma after injection [91, 92].”
BackgroundMannosylated nanoparticulate carriers of rifabutin for alveolar targeting
Nimje, N., Agarwal, A., Saraogi, G. K., Lariya, N., Rai, G., Agrawal, H., & Agrawal, G. P. (2009) · Journal of Drug Targeting · doi:10.3109/10611860903115308 · Cited by 137
“Coating of nanoparticles with a suitable biocompatible molecule may help in their improved localization in the lung tissues probably because of preferred uptake by alveolar macrophages (Soppimath et al., 2001; Vyas & Khar, 2002; Bala, Hariharan, & Kumar, 2004; Gelperina et al., 2005).”
BackgroundPoudel, P., & Park, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040835 · Cited by 124
Nanoparticle-based therapy for respiratory diseases
SILVA, A. L. D., SANTOS, R. S., XISTO, D. G., ALONSO, S. D. V., MORALES, M. M., & ROCCO, P. R. M. (2013) · Anais da Academia Brasileira de Ciências · doi:10.1590/s0001-37652013005000018 · Cited by 42
Metadata
- Authors
- Gelperina, S., Kisich, K., Iseman, M. D., & Heifets, L.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-12-15
- Volume
- 172
- Issue
- 12
- Pages
- 1487-1490
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2038864652
- Cited by
- 745
- References
- 31
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.